Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIVID-2 long-term extension study of mirikizumab in Crohn's disease
CTR20212642Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of mirikizumab in Crohn's disease, sponsored by Eli Lilly and Company. Started May 2022; status: active.
02
Drugs
mirikizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20212642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212642.